Latest Regulatory News

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

Pure Foods Tasmania Limited (ASX: PFT) will recommence trading on the ASX from 14 February 2025 following the lifting of its suspension after submitting reissued financial statements with an unqualified audit opinion.

Pure Foods Tasmania has executed key loan extensions with Commonwealth Bank and outlined a comprehensive turnaround strategy to address its financial challenges, despite ongoing material uncertainty over its going concern status.

Embelton Limited has announced a fully franked ordinary dividend of AUD 0.15 per share for the six months ending December 2024, signaling steady shareholder returns.

Delta Lithium has revealed significant progress in its Western Australian lithium and gold assets, underpinned by robust resource estimates and ongoing exploration. The company’s strategic focus on capital discipline and monetising gold positions it well for future growth.

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.

VHM Limited has unveiled a staged development plan for its Goschen Rare Earths and Mineral Sands Project, targeting first production by late 2026 and a scalable expansion to 5Mtpa by 2029 with robust financial returns.

Althea Group Holdings has sharply downgraded its FY25 financial guidance, citing significant challenges in its medicinal cannabis division and the strategic withdrawal from a vape product initiative. Despite the setback, the company highlights ongoing growth in its recreational cannabis operations and a strategic refocus on capital efficiency.

Neurotech International has inked a development deal with RH Farma to produce a pharmaceutical-grade cannabinoid drug targeting pediatric neurodevelopmental disorders, leveraging advanced European extraction technology.

Bounty Oil & Gas, through its joint venture operator Asset Energy, has initiated a judicial review against the refusal to vary and extend the PEP-11 offshore petroleum exploration permit. The legal challenge could reshape the future of this key Sydney Basin asset.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.